These findings support the novel evidence that targeting STK32C suppresses colon cancer progression and suggest its combinatorial potential with 5-FU via HSP90 and PI3K/AKT/mTOR signaling axis (Figure 10). This evidence concerns the gene MTOR and malignant colon neoplasm.